Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy

BackgroundApical hypertrophic cardiomyopathy (ApHCM) is considered a ‘benign’ form of hypertrophic cardiomyopathy, with limited data on the long-term outcome. However, the clinical impact of atrial fibrillation (AF) in ApHCM is largely unknown. The hypothesis was that AF is common and has a prognost...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heart (British Cardiac Society) 2017-10, Vol.103 (19), p.1496-1501
Hauptverfasser: Lee, Sang-Eun, Park, Jin-Kyu, Uhm, Jae-Sun, Kim, Jong Youn, Pak, Hui-Nam, Lee, Moon-Hyoung, Joung, Boyoung
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundApical hypertrophic cardiomyopathy (ApHCM) is considered a ‘benign’ form of hypertrophic cardiomyopathy, with limited data on the long-term outcome. However, the clinical impact of atrial fibrillation (AF) in ApHCM is largely unknown. The hypothesis was that AF is common and has a prognostic implication in ApHCM.MethodsThe occurrence of AF and outcome was assessed in 306 consecutive patients with ApHCM (68% male, 62±11 years).ResultsAF occurred in 77 patients with ApHCM (prevalence, 25.2%; annual incidence, 4.6%/year) and was independently predicted by old age and large left atrium (>45 mm). Among 70 AF patients indicated with anticoagulation, 53 patients (76%) received warfarin. During a follow-up of 5.5±2.0 years, the patients with AF had a higher incidence of all-cause death, cardiovascular death and strokes (11.7% vs 1.3%, 6.5% vs 0.9% and 19.5% vs 2.6%, respectively, all p
ISSN:1355-6037
1468-201X
DOI:10.1136/heartjnl-2016-310720